Real Life Sciences Japan to attend the 15th DIA Annual Meeting 2018

Real Life Sciences Japan will be exhibiting at DIA 2018, an event which showcases innovation and advances that are occurring in the medical industry both here in Japan and internationally.

The theme for this year is ‘Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation.’

Japan possesses the second largest medical industry in the world. Due to economic and demographic factors it is likely this economy will continue to expand. DIA will give attendees a chance to learn more about how Japan is going to meet this growing demand along with advancements in the industry.

DIA attracts some of the most prevalent names in the industry, we look forward to see our clients and industry partners there.  

 

What will the event cover?

AI

With an increasing number of pharma companies in Japan who are starting to venture into areas such as AI in drug discovery, health services and even medical devices, AI is a huge topic to be discussed at DIA. Furthermore, with the aging population, AI serves as a support and form of assistance to ease the burden in shortage of medical practitioners and specialists, along with other pharma manufacturers.

Big data in genomics

The ability to collect and access vast data sets, such as a patient's entire genome, has transformed the way we look at diseases, and it’s driving change across healthcare systems in Japan. What was once perceived to be time consuming and cost ineffective is now becoming increasingly manageable by connecting electronic records from hospitals, health centers and medical practices to generate, analyse and provide a portal for doctors in real time with the use of big data.

Cell and gene therapies

Japan’s rapidly aging population creates a perfect testing ground for gene therapies, and regenerative medication. The Japanese Gene Therapy Research Institution is also renowned for possessing the best capabilities in terms of talent and skills. As such, this has led to an influx of foreign partnerships, research studies, and licensing deals in the country as global companies are enticed to conduct R&D in Japan for various innovative medical products.

Currently, the sector is at the forefront in scoring research partnerships between private biotech companies and Japanese universities and is portraying a very exciting outlook for the industry in the next few years.

 

Details of the event

Venue: Tokyo Big Sight

Date: November 11-13, 2018

Booth: No.9

As the scene for healthcare product development becomes increasingly global, there is also no better time to deepen the discussion on how we can leverage on the individual strengths of countries. From promoting better collaboration, to strengthening global partnerships, Japan is on a journey to build a conducive ecosystem for creating medication, medical devices, and regenerative medical products. DIA will be an event to look forward to, that will conduct sessions on various topics mentioned above.

To get updated on the latest industry trends as well as contribute to the industry in terms of talent insights, Real Life Sciences Japan will be having a booth at this much anticipated event. If you’d like to find out more, get connected with us at [email protected] for more updates. You may also visit our website at www.realstaffing.com for more industry related insights. For more information about the event, do also visit DIA’s Global website.

Keep a look out for more updates closer to the event and we hope to see you there! 

 

Lab

How can Medical Devices Manufacturing impact Regulatory Affairs jobs in Singapore?

21 Mar 2022

Despite an increase in production and supply, quality of products and equipment need to maintain. As such, regulatory roles play a significant role in this chain to ensure that manufacturing plants remain compliant with standards and regulations.

Be a good manager with new normal leadership qualities

27 Aug 2021

Leadership have evolved tremendously over the years in an age of innovation and disruption. Now, leadership styles are gravitating towards a ‘transformational’ approach.

Updates to CPF Contribution for Employers 2021

27 Sep 2021

Compliance to regulation standards in Singapore are crucial and this is especially so for pharmaceuticals and manufacturing facilities where it should be deemed a priority. This blog will support you in understanding the employment requirements in Singapore, to ensure your company is compliant with CPF board Singapore.

MRや医療業界における2021年の転職動向まとめ

Will South Korea become Asia’s next pharmaceutical and manufacturing hub ?

01 Mar 2022

Find out what are the top strategies South Korea is planning to adopt to promote the growth in their pharmaceutical, medical device, and life sciences industries by 2030.